Empagliflozin, sold under the brand name Jardiance ( ), among others, is an antidiabetic medication used to improve glucose control in people with type2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth.
via PubMed
Empagliflozin, sold under the brand name Jardiance ( ), among others, is an antidiabetic medication used to improve glucose control in people with type2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth.
Common side effects of empagliflozin include genital yeast infections and hypotension, particularly in patients with volume depletion. Other symptoms such as nausea and vomiting may occur and seem more pronounced in combination with metformin. Rare but serious adverse events, such as euglycemic diabetic ketoacidosis (DKA) which may present with hyperventilation, lethargy, or mental status changes have been reported but are infrequent in trials. Other serious but rare serious adverse events include Fournier's gangrene, a severe skin infection of the groin, and diabetic ketoacidosis that may occur even with normal blood glucose levels. Use during pregnancy or breastfeeding is not recommended.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).